General Information of Drug (ID: DM2B9E0)

Drug Name
AT13387 Drug Info
Synonyms AT-13387
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 1 [1]
Therapeutic Class
Anticancer Agents
Cross-matching ID
PubChem CID
11955716
ChEBI ID
CHEBI:140592
CAS Number
CAS 912999-49-6
TTD Drug ID
DM2B9E0

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Heat shock protein 90 alpha (HSP90A) TT78R5H HS90A_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Heat shock protein 90 alpha (HSP90A) DTT HSP90AA1 9.604 9.034 9.856 9.2
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Melanoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Heat shock protein 90 alpha (HSP90A) DTT HSP90AA1 3.96E-01 0.18 0.48
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
2 Astex Presents Updates on AT13387, its HSP90 Inhibitor, and AT9283, its Multi-Targeted Kinase Inhibitor at the EORTC-NCI-AACR Cancer Conference. Astex. 2008.